InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,952.00
(
-0.19%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.62
(
0.09%
)
Bitcoin
57,687.22
(
-0.95%
)
Post# of 251670
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rwdm post# 187206

Sunday, 02/08/2015 1:57:56 PM

Sunday, February 08, 2015 1:57:56 PM

Post# of 251670
Hanwha’s Enbrel FoB collaboration evidently with Merck KGaA (not MRK)—i.e. Gabi Online got the story wrong:

http://news.mk.co.kr/english/newsRead.php?sc=30800006&cm=English%20News_&year=2015&no=72951&selFlag=&relatedcode=&wonNo=&sID=308

South Korea-based drugmaker Hanwha Chemical will license out its biosimilar of an arthritis drug Enbrel to a German multinational pharmaceutical firm, Merck KGaA.

…Hanhwa had a bitter experience, in which it went into partnership with US-based Merck Sharp & Dohme [i.e. MRK] in 2011 but received a notice of cancellation of contract in the following year. …the contract was cancelled because of MSD’s revision of business strategy for biosimilar.

H/t @biosimilarz.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up